ALK;ROS1 drugs for Non-Small Cell Lung Cancer
5 tracked ALK;ROS1 drugs in the Non-Small Cell Lung Cancer race. The class explanation lives on the ALK;ROS1 page; the full indication pipeline across every mechanism is on the Non-Small Cell Lung Cancer page.
1 approved / phase 44 Phase 3
Head-to-head evidence: Deulorlatinib vs Iruplinalkib · Dirozalkib (XZP-3621) vs Foritinib succinate · Dirozalkib (XZP-3621) vs Lorlatinib · Foritinib succinate vs Lorlatinib